Modality
Gene Therapy
MOA
RAS(ON)i
Target
BET
Pathway
Neuroinflam
EoE
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
Aug 2019
→ Oct 2026
Phase 2Current
NCT04823192
149 pts·EoE
2019-08→2026-10·Active
149 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-116mo awayPh2 Data· EoE
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Active
Catalysts
Ph2 Data
2026-10-11 · 6mo away
EoE
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04823192 | Phase 2 | EoE | Active | 149 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 |